{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:23:36Z","timestamp":1790684616122,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Both allergen-specific IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease characteristics in large COPD cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>COSYCONET is a comprehensively characterized cohort of patients with COPD: total IgE and IgE specific to common aeroallergens were measured in serum of 2280 patients, and related to clinical characteristics of the patients. WISDOM is another large COPD population (2477 patients): this database contains the information whether total IgE in serum was elevated (\u2265\u2009100\u00a0IU\/l) or normal in patients with COPD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both in COSYCONET and WISDOM, total IgE was elevated (\u2265\u2009100\u00a0IU\/l) in\u2009&gt;\u200930% of the patients, higher in men than in women, and higher in currently than in not currently smoking men. In COSYCONET, total IgE was elevated in patients with a history of asthma and\/or allergies. Men with at least one exacerbation in the last 12\u00a0months (50.6% of all men in COSYCONET) had higher median total IgE (71.3\u00a0IU\/l) than men without exacerbations (48.3\u00a0IU\/l): this difference was also observed in the subgroups of not currently smoking men and of men without a history of asthma. Surprisingly, a history of exacerbations did not impact on total IgE in women with COPD. Patients in the highest tertiles of total IgE (&gt;\u200991.5\u00a0IU\/ml, adjusted OR: 1.62, 95% CI 1.12\u20132.34) or allergen-specific IgE (&gt;\u20090.19\u00a0IU\/ml, adjusted OR: 2.15, 95% CI 1.32\u20133.51) were at risk of lung function decline (adjusted by: age, gender, body mass index, initial lung function, smoking status, history of asthma, history of allergy).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These data suggest that IgE may play a role in specific COPD subgroups. Clinical trials using antibodies targeting the IgE pathway (such as omalizumab), especially in men with recurrent exacerbations and elevated serum IgE, could elucidate potential therapeutic implications of our observations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-021-01847-0","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T12:02:42Z","timestamp":1641297762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["IgE is associated with exacerbations and lung function decline in COPD"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-9348","authenticated-orcid":false,"given":"Marek","family":"Lommatzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timotheus","family":"Speer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"J\u00f6rres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Watz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-9535","authenticated-orcid":false,"given":"Robert","family":"Bals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the COSYCONET study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"1847_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","volume":"115","author":"S Holgate","year":"2005","unstructured":"Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309\u201316.","journal-title":"Allergy"},{"key":"1847_CR3","doi-asserted-by":"publisher","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","volume":"51","author":"M Humbert","year":"2018","unstructured":"Humbert M, Taille C, Mala L, Le Gros V, Just J, Molimard M. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51:1702523.","journal-title":"Eur Respir J"},{"key":"1847_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1056\/NEJM198902023200502","volume":"320","author":"B Burrows","year":"1989","unstructured":"Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320:271\u20137.","journal-title":"N Engl J Med"},{"key":"1847_CR5","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1183\/09031936.96.09091880","volume":"9","author":"J Sunyer","year":"1996","unstructured":"Sunyer J, Anto JM, Castellsague J, Soriano JB, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. Eur Respir J. 1996;9:1880\u20134.","journal-title":"Eur Respir J"},{"key":"1847_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/thoraxjnl-2013-203738","volume":"69","author":"M Lommatzsch","year":"2014","unstructured":"Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax. 2014;69:94\u20136.","journal-title":"Thorax"},{"key":"1847_CR7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","volume":"141","author":"MA Gill","year":"2018","unstructured":"Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, Gern JE, Togias A, Busse WW. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141:1735-1743.e1739.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR8","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","volume":"136","author":"SJ Teach","year":"2015","unstructured":"Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, Wildfire JJ, Gergen PJ, Cohen RT, Pongracic JA, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476\u201385.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","volume":"196","author":"A Esquivel","year":"2017","unstructured":"Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, Gruchalla RS, Kattan M, Kercsmar CM, Khurana Hershey G, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196:985\u201392.","journal-title":"Am J Respir Crit Care Med"},{"key":"1847_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1159\/000506651","volume":"99","author":"M Lommatzsch","year":"2020","unstructured":"Lommatzsch M. Immune modulation in asthma: current concepts and future strategies. Respiration. 2020;99:566\u201376.","journal-title":"Respiration"},{"key":"1847_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/cea.12664","volume":"46","author":"P Stoll","year":"2016","unstructured":"Stoll P, Bahker A, Ulrich M, Bratke K, Garbe K, Christian Virchow J, Lommatzsch M. The dendritic cell high-affinity IgE receptor is overexpressed in both asthma and severe COPD. Clin Exp Allergy. 2016;46:575\u201383.","journal-title":"Clin Exp Allergy"},{"key":"1847_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/thx.2006.072777","volume":"62","author":"H Makita","year":"2007","unstructured":"Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, Onodera Y, Hizawa N, Nishimura M. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007;62:932\u20137.","journal-title":"Thorax"},{"key":"1847_CR13","first-page":"86","volume":"73","author":"B Singh","year":"2010","unstructured":"Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis. 2010;73:86\u20137.","journal-title":"Monaldi Arch Chest Dis"},{"key":"1847_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12931-014-0130-1","volume":"15","author":"J Jin","year":"2014","unstructured":"Jin J, Liu X, Sun Y. The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and lung function. Respir Res. 2014;15:130.","journal-title":"Respir Res"},{"key":"1847_CR15","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.chest.2020.04.069","volume":"158","author":"N Putcha","year":"2020","unstructured":"Putcha N, Fawzy A, Matsui EC, Liu MC, Bowler RP, Woodruff PG, O\u2019Neal WK, Comellas AP, Han MK, Dransfield MT, et al. Clinical phenotypes of atopy and asthma in COPD: a meta-analysis of SPIROMICS and COPDGene. Chest. 2020;158:2333\u201345.","journal-title":"Chest"},{"key":"1847_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1164\/rccm.201211-2103OC","volume":"188","author":"DB Jamieson","year":"2013","unstructured":"Jamieson DB, Matsui EC, Belli A, McCormack MC, Peng E, Pierre-Louis S, Curtin-Brosnan J, Breysse PN, Diette GB, Hansel NN. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:187\u201392.","journal-title":"Am J Respir Crit Care Med"},{"key":"1847_CR17","first-page":"1","volume":"7","author":"CP Hersh","year":"2020","unstructured":"Hersh CP, Zacharia S, Chelvan PAR, Hayden LP, Mirtar A, Zarei S, Putcha N. Immunoglobulin E as a biomarker for the overlap of atopic asthma and chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2020;7:1\u201312.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"1847_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","volume":"4","author":"H Watz","year":"2016","unstructured":"Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390\u20138.","journal-title":"Lancet Respir Med"},{"key":"1847_CR19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285\u201394.","journal-title":"N Engl J Med"},{"key":"1847_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.rmed.2016.03.008","volume":"114","author":"A Karch","year":"2016","unstructured":"Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Glaser S, Holle R, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27\u201337.","journal-title":"Respir Med"},{"key":"1847_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2017.12.003","volume":"134","author":"K Kahnert","year":"2018","unstructured":"Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018;134:79\u201385.","journal-title":"Respir Med"},{"key":"1847_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000237398","volume":"111","author":"B Wuthrich","year":"1996","unstructured":"Wuthrich B, Schindler C, Medici TC, Zellweger JP, Leuenberger P. IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team. Int Arch Allergy Immunol. 1996;111:396\u2013402.","journal-title":"Int Arch Allergy Immunol"},{"key":"1847_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1365-2222.1994.tb00950.x","volume":"24","author":"E Omenaas","year":"1994","unstructured":"Omenaas E, Bakke P, Elsayed S, Hanoa R, Gulsvik A. Total and specific serum IgE levels in adults: relationship to sex, age and environmental factors. Clin Exp Allergy. 1994;24:530\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1847_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2249.1994.tb06533.x","volume":"95","author":"KA Byron","year":"1994","unstructured":"Byron KA, Varigos GA, Wootton AM. IL-4 production is increased in cigarette smokers. Clin Exp Immunol. 1994;95:333\u20136.","journal-title":"Clin Exp Immunol"},{"key":"1847_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0091-6749(92)90075-D","volume":"90","author":"EJ Jensen","year":"1992","unstructured":"Jensen EJ, Pedersen B, Schmidt E, Dahl R. Serum IgE in nonatopic smokers, nonsmokers, and recent exsmokers: relation to lung function, airway symptoms, and atopic predisposition. J Allergy Clin Immunol. 1992;90:224\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1365-2222.1995.tb03255.x","volume":"25","author":"D Jarvis","year":"1995","unstructured":"Jarvis D, Luczynska C, Chinn S, Burney P. The association of age, gender and smoking with total IgE and specific IgE. Clin Exp Allergy. 1995;25:1083\u201391.","journal-title":"Clin Exp Allergy"},{"key":"1847_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaci.2013.12.1071","volume":"134","author":"PM Salo","year":"2014","unstructured":"Salo PM, Arbes SJ Jr, Jaramillo R, Calatroni A, Weir CH, Sever ML, Hoppin JA, Rose KM, Liu AH, Gergen PJ, et al. Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005\u20132006. J Allergy Clin Immunol. 2014;134:350\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4168\/aair.2017.9.4.329","volume":"9","author":"HJ Park","year":"2017","unstructured":"Park HJ, Kim EJ, Yoon D, Lee JK, Chang WS, Lim YM, Park JW, Lee JS. Prevalence of self-reported allergic diseases and IgE Levels: a 2010 KNHANES analysis. Allergy Asthma Immunol Res. 2017;9:329\u201339.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1847_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2006.09.008","volume":"118","author":"SJ Uekert","year":"2006","unstructured":"Uekert SJ, Akan G, Evans MD, Li Z, Roberg K, Tisler C, Dasilva D, Anderson E, Gangnon R, Allen DB, et al. Sex-related differences in immune development and the expression of atopy in early childhood. J Allergy Clin Immunol. 2006;118:1375\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/ijms19061554","volume":"19","author":"J Leffler","year":"2018","unstructured":"Leffler J, Stumbles PA, Strickland DH. Immunological processes driving IgE sensitisation and disease development in males and females. Int J Mol Sci. 2018;19:1554.","journal-title":"Int J Mol Sci"},{"key":"1847_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/ntr\/ntx247","volume":"21","author":"JJ Dong","year":"2019","unstructured":"Dong JJ, Shen JJ, Lee YJ. Dose-dependent effect of cotinine-verified tobacco smoking on serum immunoglobulin E levels in korean adult males. Nicotine Tob Res. 2019;21:813\u20137.","journal-title":"Nicotine Tob Res"},{"key":"1847_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2222.1995.tb01030.x","volume":"25","author":"MT Villar","year":"1995","unstructured":"Villar MT, Holgate ST. IgE, smoking and lung function. Clin Exp Allergy. 1995;25:206\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1847_CR33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/thoraxjnl-2018-213035","volume":"74","author":"E Sapey","year":"2019","unstructured":"Sapey E, Bafadhel M, Bolton CE, Wilkinson T, Hurst JR, Quint JK. Building toolkits for COPD exacerbations: lessons from the past and present. Thorax. 2019;74:898\u2013905.","journal-title":"Thorax"},{"key":"1847_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/thoraxjnl-2019-214484","volume":"75","author":"AG Mathioudakis","year":"2020","unstructured":"Mathioudakis AG, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen JS, Vestbo J. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75:520\u20137.","journal-title":"Thorax"},{"key":"1847_CR35","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/resp.12780","volume":"21","author":"FW Ko","year":"2016","unstructured":"Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, Yang IA. Acute exacerbation of COPD. Respirology. 2016;21:1152\u201365.","journal-title":"Respirology"},{"key":"1847_CR36","doi-asserted-by":"publisher","first-page":"1901592","DOI":"10.1183\/13993003.01592-2019","volume":"55","author":"C Bachert","year":"2020","unstructured":"Bachert C, Humbert M, Hanania NA, Zhang N, Holgate S, Buhl R, Br\u00f6ker BM. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Eur Respir J. 2020;55:1901592.","journal-title":"Eur Respir J"},{"key":"1847_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMra1900475","volume":"381","author":"A Agusti","year":"2019","unstructured":"Agusti A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019;381:1248\u201356.","journal-title":"N Engl J Med"},{"key":"1847_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1378\/chest.101.3.642","volume":"101","author":"I Annesi","year":"1992","unstructured":"Annesi I, Oryszczyn MP, Frette C, Neukirch F, Orvoen-Frija E, Kauffmann F. Total circulating IgE and FEV1 in adult men. An epidemiologic longitudinal study. Chest. 1992;101:642\u20138.","journal-title":"Chest"},{"key":"1847_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1164\/ajrccm.151.3.7881652","volume":"151","author":"M Tracey","year":"1995","unstructured":"Tracey M, Villar A, Dow L, Coggon D, Lampe FC, Holgate ST. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1. A longitudinal study in the elderly. Am J Respir Crit Care Med. 1995;151:656\u201362.","journal-title":"Am J Respir Crit Care Med"},{"key":"1847_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1164\/ajrccm.152.1.7599870","volume":"152","author":"DL Sherrill","year":"1995","unstructured":"Sherrill DL, Lebowitz MD, Halonen M, Barbee RA, Burrows B. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J Respir Crit Care Med. 1995;152:98\u2013102.","journal-title":"Am J Respir Crit Care Med"},{"key":"1847_CR41","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.jaci.2019.01.018","volume":"143","author":"J Schreiber","year":"2019","unstructured":"Schreiber J, Broker BM, Ehmann R, Bachert C. Nonatopic severe asthma might still be atopic: sensitization toward Staphylococcus aureus enterotoxins. J Allergy Clin Immunol. 2019;143:2279-2280.e2272.","journal-title":"J Allergy Clin Immunol"},{"key":"1847_CR42","doi-asserted-by":"publisher","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","volume":"53","author":"D Singh","year":"2019","unstructured":"Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:1900164.","journal-title":"Eur Respir J"},{"key":"1847_CR43","doi-asserted-by":"publisher","unstructured":"Lommatzsch M, Klein M, Stoll P, Virchow JC. Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma. Allergy. 2021. In press. https:\/\/doi.org\/10.1111\/all.14997.","DOI":"10.1111\/all.14997"},{"key":"1847_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12931-019-1130-y","volume":"20","author":"CF Vogelmeier","year":"2019","unstructured":"Vogelmeier CF, Kostikas K, Fang J, Tian H, Jones B, Morgan CL, Fogel R, Gutzwiller FS, Cao H. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20:178.","journal-title":"Respir Res"},{"key":"1847_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/thoraxjnl-2018-212233","volume":"74","author":"M Lommatzsch","year":"2019","unstructured":"Lommatzsch M, Klein M, Stoll P, Virchow JC. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma. Thorax. 2019;74:417\u20138.","journal-title":"Thorax"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01847-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T09:12:11Z","timestamp":1666429931000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01847-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01847-0","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approvals and patient consents are detailed in the publications describing the study design and the primary results of COSYCONET and WISDOM [\u2013].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given final approval of the version submitted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest regarding this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}